申请人:Chemgenex Pharmaceuticals, Inc.
公开号:US07842687B2
公开(公告)日:2010-11-30
The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula:
wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine),
in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.
本发明涉及一种新的不对称半合成哈林顿碱及其类似物的通用过程,这些生物碱用于化疗。该过程包括将天然头孢松碱直接酯化为一个酰化化合物,该酰化化合物由一个侧链前体组成,其骨架和功能化已完全形成。本发明还涉及以下式子的天然、合成或半合成的哈林顿碱及其互变异构体和盐:其中n = 2(即哈林顿碱)或n = 3(即同型哈林顿碱),其中可能包括对映异构体的杂质总含量低于1%,主要杂质的含量低于0.9%,或色谱分析显示哈林顿碱含量高于97.5%。